ASCO 2020 Breast/Gyn

CME

Key Studies in Breast and Gynecologic Cancers: Independent Conference Coverage of the 2020 ASCO Virtual Scientific Meeting

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: September 09, 2020

Expiration: September 08, 2021

Sara Hurvitz
Sara Hurvitz, MD

Activity

Progress
1
Course Completed

References

  1. Khan SA, Zhao F, Solin LJ, et al. A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108). Program and abstracts of the 2020 ASCO Virtual Meeting; May 29-31, 2020. Abstract LBA2.
  2. Badwe R, Hawaldar R, Nair N, et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Lancet Oncol. 2015;16:1380-1388.
  3. Soran A, Ozmen V, Ozbas S, et al. Randomized trial comparing resection of primary tumor with no surgery in stage IV breast cancer at presentation: protocol MF07-01. Ann Surg Oncol. 2018;25:3141-3149.
  4. Lin NU, Murthy RK, Anders CK, et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB). Program and abstracts of the 2020 ASCO Virtual Meeting; May 29-31, 2020. Abstract 1005.
  5. Lin NU, Borges V, Anders C, et al. Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol. 2020;Epub ahead of print.
  6. Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382:597-609.
  7. Cortes J, Cescon DW, Rugo HS, et al. KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. Program and abstracts of the 2020 ASCO Virtual Meeting; May 29-31, 2020. Abstract 1000.
  8. Adams S, Scmid P, Rugo HS, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30:397-404.
  9. Adams S, Loi S, Toppmeyer D, et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30:405-411.
  10. Nanda R, Chow LQM, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol. 2016;34:2460-2467.
  11. Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810-821.
  12. Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108-2121.
  13. Rugo HS, Lerebours F, Ciruelos E, et al. Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYLieve study results. Program and abstract of of the 2020 ASCO Virtual Meeting; May 29-31, 2020. Abstract 1006.
  14. Mukohara T. PI3K mutations in breast cancer: prognostic and therapeutic implications. Breast Cancer (Dove Med Press). 2015;7:111-123.
  15. Sobhani N, Roviello G, Corona SP, et al. The prognostic value of PI3K mutational status in breast cancer: a meta-analysis. J Cell Biochem. 2018;119:4287-4292.
  16. Mosele F, Stefanovska B, Lusque A, et al. Outcome and molecular landscape ofpatients with PIK3CA-mutated metastatic breast cancer. Ann Oncol. 2020;31:377-386.
  17. Moynahan ME, Chen D, He W, et al. Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2-advanced breast cancer: results from BOLERO-2. Br J Cancer. 2017;116:726-730.
  18. Di Leo A, Johnston S, Lee KS, et al. Lancet Oncol. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. 2018;19:87.
  19. Rugo HS, Ruiz Borrego M, Chia SK, et al. Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor-2-negative (HER2-) advanced breast cancer (ABC): first interim BYLieve study results. Program and abstracts of the 2019 ASCO annual meeting; May 31 - June 4, 2019; Chicago, Illinois. Abstract 1040.
  20. Juric D, Ciruelos E, Rubovszky G, et al. Alpelisib + fulvestrant for advanced breast cancer: subgroup analyses from the phase III SOLAR-1 trial. Program and abstracts of the 2018 San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, Texas. Abstract GS3-08.
  21. André F, Ciruelos EM, Rubovsky G, et al. Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): results of the phase 3 SOLAR-1 trial. Program and abstracts of the 2018 European Society of Medical Oncology; October 19-23, 2018; Munich, Germany. Abstract LBA3.
  22. Olaparib package insert. Wilmington, DE: AstraZeneca; 2020.
  23. Rucaparib package insert. Boulder, CO: Clovis Oncology; 2020.
  24. Niraparib package insert. Research Triangle Park, NC: GlaxoSmithKline; 2020.
  25. Poveda A, Floquet A, Ledermann JA, et al. Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation. Program and abstracts of the 2020 ASCO Virtual Meeting; May 29-31, 2020. Abstract 6002.
  26. Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1274-1284.
  27. Mirza MR, Avall Lundqvist E, Birrer MJ, et al. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. Lancet Oncol. 2019;20:1409-1419.
  28. Mirza MR, Nyvang G-B, Lund B, et al. Final survival analysis of NSGO-AVANOVA2/ENGOT-OV24: Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer—a randomized controlled chemotherapy-free study. Program and abstracts of the 2020 ASCO Virtual Meeting; May 29-31, 2020. Abstract 6012.
  29. Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381:2416-2428.
  30. Liu JF, Barry WT, Birrer M, et al. Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Ann Oncol. 2019;30:551-557.
  31. Matulonis UA, Shapira R, Santin A, et al. Final results from the KEYNOTE-100 trial of pembrolizumab in patients with advanced recurrent ovarian cancer. Program and abstracts of the 2020 ASCO Virtual Meeting; May 29-31, 2020. Abstract 6005.
  32. Varga A, Piha-Paul SA, Ott PA, et al. Pembrolizumab in patients (pts) with PD-L1–positive (PD-L1+) advanced ovarian cancer: updated analysis of KEYNOTE-028. Program and abstracts of the 2017 ASCO Annual Meeting; June 2-6, 2017; Chicago, Illinois. Abstract 5513.
  33. Matulonis UA, Shapria-Frommer R, Santin AD, et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol. 2019;30:1080-1087.
  34. Eskander RN, Ledermann JA, Birrer MJ, et al. JAVELIN ovarian PARP 100 study design: phase III trial of avelumab + chemotherapy followed by avelumab + talazoparib maintenance in previously untreated epithelial ovarian cancer. Program and abstracts of the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium; February 28 - March 2, 2019; San Francisco, California. Abstract TPS9.
  35. Pujade-Lauraine E, Fujiwara K, Ledermann JA, et al. Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: primary and biomarker analysis of the phase III JAVELIN Ovarian 200 trial. Program and abstracts of the 2019 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer; March 16-19, 2019; Honolulu, Hawaii. Abstract LBA1.
  36. ClinicalTrials.gov. NCT03038100. A study of atezolizumab versus placebo in combination with paclitaxel, carboplatin, and bevacizumab in participants with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer (IMagyn050). Available at: https://clinicaltrials.gov/ct2/show/NCT03038100. Accessed August 28, 2020.